6xuz

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (13:13, 24 January 2024) (edit) (undo)
 
(2 intermediate revisions not shown.)
Line 1: Line 1:
==CRYSTAL STRUCTURE OF BRD4-BD1 WITH COMPOUND 4==
==CRYSTAL STRUCTURE OF BRD4-BD1 WITH COMPOUND 4==
-
<StructureSection load='6xuz' size='340' side='right'caption='[[6xuz]]' scene=''>
+
<StructureSection load='6xuz' size='340' side='right'caption='[[6xuz]], [[Resolution|resolution]] 1.07&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XUZ OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6XUZ FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[6xuz]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6XUZ OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6XUZ FirstGlance]. <br>
-
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6xuz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xuz OCA], [http://pdbe.org/6xuz PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6xuz RCSB], [http://www.ebi.ac.uk/pdbsum/6xuz PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6xuz ProSAT]</span></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.07&#8491;</td></tr>
 +
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=O1W:6-[1-[(2~{S})-1-methoxypropan-2-yl]-6-[(3~{S})-3-methylmorpholin-4-yl]imidazo[4,5-c]pyridin-2-yl]-3-methyl-~{N}-propan-2-yl-[1,2,4]triazolo[4,3-a]pyrazin-8-amine'>O1W</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6xuz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6xuz OCA], [https://pdbe.org/6xuz PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6xuz RCSB], [https://www.ebi.ac.uk/pdbsum/6xuz PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6xuz ProSAT]</span></td></tr>
</table>
</table>
 +
== Disease ==
 +
[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN] Note=A chromosomal aberration involving BRD4 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;19)(q14;p13) with NUT which produces a BRD4-NUT fusion protein.<ref>PMID:12543779</ref> <ref>PMID:11733348</ref>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/BRD4_HUMAN BRD4_HUMAN] Plays a role in a process governing chromosomal dynamics during mitosis (By similarity).
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
While CH-pi-interactions with target proteins are crucial determinants for the affinity of arguably every drug molecule, no method exists to directly measure the strength of individual CH-pi interactions in drug-protein complexes. Here we present a fast and reliable methodology called PI (pi interactions) by NMR, which can differentiate the strength of protein-ligand CH-pi interactions in solution. By combining selective amino-acid side-chain labeling with 1 H- 13 C NMR, we are able to identify specific protein protons of side-chains engaged in CH-pi interactions with aromatic ring-systems of a ligand, based solely on 1 H chemical shift values of the interacting protein aromatic ring protons. The information encoded in the chemical shifts induced by such interactions serves as a proxy for the strength of each individual CH-pi interaction. PI by NMR changes the paradigm by which chemists can optimize the potency of drug candidates: direct determination of individual pi-interactions rather than averaged measures of all interactions.
 +
 +
PI by NMR: Probing CH-pi Interactions in Protein-Ligand Complexes by NMR.,Platzer G, Mayer M, Beier A, Bruschweiler S, Fuchs JE, Engelhardt H, Geist L, Bader G, Schorghuber J, Lichtenecker R, Wolkersdorfer B, Kessler D, McConnell DB, Konrat R Angew Chem Int Ed Engl. 2020 May 18. doi: 10.1002/anie.202003732. PMID:32421895<ref>PMID:32421895</ref>
 +
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 6xuz" style="background-color:#fffaf0;"></div>
 +
== References ==
 +
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
 +
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Large Structures]]
[[Category: Bader G]]
[[Category: Bader G]]
[[Category: Kessler D]]
[[Category: Kessler D]]
[[Category: Wolkerstorfer B]]
[[Category: Wolkerstorfer B]]

Current revision

CRYSTAL STRUCTURE OF BRD4-BD1 WITH COMPOUND 4

PDB ID 6xuz

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools